O ver the last 2 decades, numerous studies have shown a positive relationship between volume and health outcomes for a variety of surgical procedures and medical conditions (1) (2) (3) . The primary hypothesis explaining this association is that providers treating more patients acquire better skills and that hospitals with high volume develop more consistent processes of care and therefore have better resources for taking care of patients with that condition (1) (2) (3) .
Numerous randomized controlled trials and large observational studies have shown that noninvasive ventilation (NIV) reduces the rate of endotracheal intubation and decreases mortality in patients with moderate to severe exacerbations of chronic obstructive pulmonary disease (COPD) (4-7). However, successful implementation of NIV requires an interdisciplinary team of physicians, respiratory therapists, and nurses with appropriate skills. As is the case with other complex interventions, correct selection and monitoring of patients is vital to achieving good outcomes. As providers become more experienced and comfortable using NIV, they may develop better skills in selecting patients and delivering NIV. Therefore, it is possible that, as is the case in invasive mechanical ventilation (IMV), a positive relationship between hospital volume of NIV use and patient outcomes exists (2, 8) . Only one prior study, which included patients hospitalized with COPD in ICUs in France, addressed this topic and found that ICUs with higher case volumes had an increased use of NIV and a trend toward lower mortality, suggesting that increasing experience favors the use of NIV and better outcomes (9) .
Using a large multihospital dataset, we examined the relationship between hospital experience of NIV use and the inhospital outcomes of patients with an acute exacerbation of COPD (AE-COPD) treated with NIV. We hypothesized that higher case volume of NIV use would be associated with better patient outcomes.
MATERIALS AND METHODS

Design, Setting, and Patient Characteristics
We conducted a cross-sectional study by analyzing data on patients hospitalized for COPD exacerbation, between July 2009 and June 2011, at 412 structurally and geographically diverse U.S. hospitals that participate in a voluntary, fee-supported database developed to support quality improvement (Premier Healthcare Informatics, Charlotte, NC). In addition to the information contained in the standard hospital discharge abstract, the database contains a date-indexed log of all items and services charged to patients or their insurers, including medications, laboratory and radiologic tests, and therapeutic services. Data are collected electronically from participating sites, are audited regularly to ensure data validity, and are used extensively for outcomes research (10, 11).
Patients were included if they were 40 years old or older, had a principal International Classification of Disease, 9th Revision (ICD-9) discharge diagnosis (ICD-9, Clinical Modification code) consistent with an exacerbation of COPD (491.21, 492.22, 491.8, 491.9, 492.8, 496) or a secondary diagnosis of COPD when accompanied by a principal diagnosis of acute respiratory failure (518.81, 518.82, 122,518.84), and were treated with systemic corticosteroids and bronchodilators. We excluded transfer patients, patients with obstructive sleep apnea, and those with diagnoses of contraindications for NIV if they were present at admission. We limited the study to hospitals that participated in the database for at least 1 year, and to obtain more stable estimates for the outcomes, we restricted the analysis to hospitals with more than or equal to 20 admissions of COPD treated with NIV for the period of the study.
We recorded patients' demographics, comorbidities, number of hospitalizations with COPD in the prior year, and whether NIV or IMV was used in the prior admission. Coexisting conditions were aggregated into a score, based on methods described by Gagne et al (12) . The comorbidity score is a single numerical score for predicting short-and longterm mortality by combining conditions in the Charlson and Elixhauser measures and providing a standardized summary of the burden of comorbidity (range, 0-24). (supplemental data, Supplemental Digital Content 1, http://links.lww.com/ CCM/C4)
NIV Volume
Administration of NIV and IMV was identified using two approaches. First, we reviewed ICD-9 procedure codes (for NIV: 93.90 and for IMV: 96.04, 96.70, 96.71, 96.72) and the date associated with the receipt of each procedure. Second, we used charges generated by the respiratory therapist for NIV or IMV use. We considered a patient to have received NIV or IMV during the admission if there was an ICD-9 procedure code or a charge for the procedure or service.
We chose the annual hospital volume of NIV delivered for any adult medical patient as the primary exposure variable. We used the overall hospital's experience with NIV because the availability of the technology, staff skills, and confidence in utilizing NIV would apply to all patients with acute respiratory failure in need of mechanical ventilation.
For analysis, annual hospital NIV volume was log-transformed due to a skewed distribution. We also grouped hospitals into quartiles, on the basis of their annual hospital NIV volume based on thresholds that yielded approximately equal numbers of COPD patients treated with NIV in each volume category. In a sensitivity analysis, we used annual hospital volume of NIV delivered only to patients hospitalized with AE-COPD.
Outcomes
The primary outcome measure was NIV failure, defined as transition to IMV after an initial exposure to NIV. Length of stay, in-hospital mortality, 30-day COPD, all-cause readmissions, days of NIV use, and a combined NIV failure or death were examined as secondary outcomes. 
Statistical Analysis
Patients admitted with AE-COPD and treated with NIV as the first or only method of ventilation were eligible for analysis. For patients with multiple eligible admissions during the study period, we selected one single observation per patient at random to avoid survival bias (as one of our outcomes was mortality). The Mantel Haenszel chi-square test for trend across ordinal categories of hospital NIV volume was used to evaluate association of volume with patient and hospital characteristics. Hierarchical multivariable logistic regression modeling was conducted to examine the relationship between hospital NIV volume and categoric outcomes, adjusting for possible confounders (demographics, comorbidities, number of hospitalizations with COPD in the prior year, and whether NIV or IMV was used in the prior admission) and taking in account the clustering of the data at the hospital level. Linear models were used for log-transformed length of hospital stay.
We performed several sensitivity analyses. First, we restricted the cohort to patients younger than 85 years. Second, we tested for effect modification of the relationship between NIV volume and outcomes by concomitant pneumonia and by comorbidity score. Finally, we repeated our primary analyses defining the hospital volume of NIV use restricted to patients with COPD.
Statistical analyses were performed using the Statistical Analysis System (version 9.3; SAS Institute, Cary, NC). The study was approved by the Human Subjects Review Committee of the Institutional Review Board at Baystate Medical Center.
RESULTS
Patient and Hospital Characteristics
After applying the exclusion criteria, we identified a total of 102,942 eligible admissions with an AE-COPD, at 412 hospitals. Of these, 15,474 (15.0%) received NIV as the initial ventilation strategy. After choosing one random admission per patient, and restricting to hospitals with greater than or equal to 20 admissions treated with NIV, we included in the analysis a total of 13,893 patients from 243 hospitals. (Fig. 1) The median age of the patients was 69 years, 57.6% were female, 72.3% were white, and the most frequent comorbidities were hypertension, congestive heart failure, diabetes mellitus, and depression. The median combined comorbidity score was 3 (interquartile range [IQR], 1-4), and 21.4% had a coexistent diagnosis of pneumonia at admission. Forty percent of the patients had at least one COPD admission in the year prior to the index admission, and more than one third required ventilation during a previous admission (NIV, 28.3% and IMV, 11.9%). Among all patients, in-hospital mortality was 6.5%, and the median length of hospital stay was 5 days (IQR, [4] [5] [6] [7] [8] . NIV failure occurred in 15.2% of the patients treated with initial NIV, and hospital mortality among those with NIV failure was 18.4%. Among the 243 hospitals, the NIV use for COPD patients ranged from 3.7% to 87.4%, with a median of 17.6% (IQR, 14.1-23.4%).
Hospital annual NIV volume, among all adult medical admissions ranged from 209 at the 10th percentile hospital to 1,658 at the 90th percentile, with a median of 627. The median NIV volume by quartile was 234 admissions in Q1, 489 in Q2, 757 in Q3, and 1,529 in Q4. Each quartile contained at least 3,000 admissions of patients with AE-COPD treated with NIV, and the number of hospitals included was 97 in Q1 and 35 in Q4. The median hospital volume of AE-COPD admissions was 314 (IQR, 220-442), and the annual median volume of patients treated with NIV among patients with COPD. The characteristics of patients and hospitals in each volume quartile category are shown in Table 1 . Patients admitted to highvolume hospitals were more likely to be black (Q1 6.6% to Q4 12.5%) and have hypertension, diabetes, and renal failure. There was a significant trend across NIV volume quartiles with greater use of NIV and IMV in a prior admission (p for trend < 0.05) (for NIV, Q1 11.3% to Q4 13.3%).
The percent of patients with COPD, treated with initial NIV during hospitalization, was 14.0%, 15.6%, 17.7%, and 19.0% (p < 0.001) in Q1 (lowest volume) through Q4, respectively.
Compared with low-NIV volume hospitals, high-volume hospitals were more likely to be engaged in teaching, to be located in an urban setting, and to have more beds. Hospitals with high NIV volume also had a higher number of respiratory therapists, hospitalists, and intensivists per hospital bed.
Association Between Hospital NIV Volume and Hospital Outcomes
In unadjusted analysis, hospitals in Q1 and Q4 of NIV volume had somewhat higher NIV failure rates (16.1% in Q1 and 16.9% in Q4) compared with that of Q2 and Q3 (15.3% in Q2, 12.8% in Q3, p for trends = 0.75). There was no statistically significant relationship between hospital volume across quartiles of NIV use and in-hospital mortality among COPD patients treated with NIV (p = 0.17), in-hospital mortality among those with NIV failure, 30-day readmission for COPD (p = 0.36), or length of stay (p = 0.09) ( Table 2) .
When the hospital volume was included as a continuous (log-transformed) variable in the hierarchical multivariable analysis adjusted for patient characteristics, NIV volume was not related to outcomes, including NIV failure (p = 0.88), the combined outcome of NIV failure or death (p = 0.98), inhospital mortality (p = 0.88), 30-day readmission for COPD 
DISCUSSION
In this large retrospective study of almost 14,000 patients with COPD treated with NIV at 243 hospitals in the United States, we found that patients admitted to hospitals with a higher volume of NIV use did not experience better outcomes compared with those treated at lower volume hospitals. The lack of relationship between NIV volume and outcomes, including NIV failure, mortality, length of stay, and 30-day readmission, was consistent in several sensitivity and secondary analyses, including among patients younger than 85 years old, those with and without pneumonia, those with high and low burden of comorbidity, and in an analysis that defined hospital NIV volume based on NIV experience among patients with COPD.
Over the last 2 decades, the relationship between volume and health outcomes has been the focus of much research. Numerous studies have found that care in institutions with higher case load is associated with better outcomes across a broad array of high-risk surgical and medical conditions (1-3, 8, 9, 13) . A 2002 systematic review of 135 studies of 27 procedures and clinical conditions found that, in 70% of the studies included in the analysis, high volume was associated with better outcomes (14 
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receive care at a higher volume hospital have a 5-10% lower risk of death than those being cared at a lower volume hospital (2, 8) .
In this study, we hypothesized that institutions that use more NIV would be more likely to implement high-quality organizational practices and have more experienced providers with better clinical expertise for patient selection and NIV monitoring. As such, they would achieve better outcomes than institutions with lower volume and less experience. Although hospitals varied considerably in their experience with NIV, overall and among patients with COPD, we found no appreciable relationship between the hospital NIV volume and patient outcomes after adjusting for possible confounders.
There are several possible explanations for this finding. First, the use of NIV for patients with AE-COPD has increased considerably between publication of the first randomized controlled trials of NIV use in patients with AE-COPD and the timing of this study (9, 11, 15) . It is possible that during this time, most hospitals implemented the necessary infrastructure and processes of care for delivering NIV. Second, successful use of NIV among patients with AE-COPD may be related to factors such as teamwork or hospital (or ICU) organization that may not be directly associated with NIV volume. A study of more than 70,000 patients with COPD hospitalized at 386 hospitals found that use of NIV and the outcomes associated with NIV, such as NIV failure and mortality, varied substantially across hospitals (16) . Our study shows that hospital NIV volume is not the main driving force for this variation in outcomes. Third, even hospitals in the lowest volume deciles in our study used NIV frequently for respiratory failure, with a median annual volume of 122. Thus, the volume of NIV use may have surpassed the minimum volume necessary to exceed the NIV volume-outcome inflection point. Finally, one may argue that as providers are more experienced and confident in using NIV, they employ it in patients with a higher risk of NIV failure who would have been intubated in hospitals with lower volume. In this case, the comparable NIV failure and mortality rates at lower and higher volume hospitals would be explained by the greater skill the higher volume centers applied in treating sicker patients. Our study has several strengths. We included a large number of patients treated with NIV, in a diverse group of U.S. hospitals. We performed analyses using NIV volume among all patients treated at the hospital as well as among patients with COPD and obtained similar results. Furthermore, our results were robust to alternative approaches for modeling volume and in several sensitivity analyses.
However, our findings should be interpreted in light of several limitations. First, as our analysis was based on administrative data, we may not have accounted effectively for all differences in patient case mix. Specifically, it is possible that high-volume centers are using NIV in more marginal, difficult (i.e., sicker) patients, obscuring a positive volume-outcome where one exists. Nevertheless, we controlled for several variables including prior utilization of mechanical ventilation and prior admission for COPD, and we restricted the analysis to patients treated with bronchodilators and steroids to overcome some of the limitations of using ICD-9 diagnoses for case identification. Second, we did not have information about advance directives, and in some cases, NIV could have been used for patients discharged to hospice who subsequently died outside the hospital. However, the lack of association persisted for the combined outcome of NIV failure and death, and in patients younger than 85 years old. Third, we did not have reliable information regarding the location where NIV was delivered, a factor that may influence the risk of NIV failure. Although this issue is very important, we did not have access to detailed physiologic data needed to overcome the problem of confounding by indication where sicker patients are preferentially admitted to the ICU. A recent study found that the NIV success rate was higher if NIV was delivered on the general ward than in ICU, which most likely reflects the higher acuity of the ICU patients (17) . Fourth, we could not distinguish if continuous positive airway pressure or bilevel positive airway pressure was used as they share the same procedure codes. Finally, because hospitals included in our study participate in a voluntary, fee-supported database used for quality improvement, it is possible that our sample is not entirely representative of other U.S. hospitals in their commitment to quality improvement. However, this is unlikely given the large sample size and hospital diversity with respect to other characteristics. Further studies should explore whether there is any volume-outcome relationship in a more broadly representative sample such as the Nationwide Inpatient Sample.
CONCLUSION
The results of this large retrospective cohort study suggest that hospitals with higher NIV volume do not achieve better outcomes of patients with COPD exacerbation treated with NIV; even hospitals with low NIV volume are able to successfully implement this intervention. 
